A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily Via Inhalation, for 2 Weeks, in Adults With Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs AZD 8630 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 04 Feb 2025 Status changed from not yet recruiting to recruiting.
- 03 Feb 2025 New trial record